Q2 2026 13F · SEC CIK 1802528
Fairmount Funds Management LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $1.5B
- Reported positions
- 12
- Top holdings a year, 3 yrs
- +72.8%
- Assets under management
- $5.8B
Fairmount Funds Management LLC is a hedge fund that reported 12 positions worth $1.5B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Oruka Therapeutics Inc (ORKA, 23.3%), Dianthus Therapeutics Inc (DNTH, 16.3%), Damora Therapeutics Inc (GLTO, 15.0%). A portfolio copying its top holdings returned 72.8% a year over the last 3 years, against 20.4% for the S&P 500.
Fairmount Funds Management LLC holdings all 12 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| ORKAOruka Therapeutics Inc | 23.3% | +0.0% | $352.6M |
| DNTHDianthus Therapeutics Inc | 16.3% | +0.0% | $247.3M |
| GLTODamora Therapeutics Inc | 15.0% | +0.0% | $226.6M |
| COGTCogent Biosciences Inc | 14.1% | +0.0% | $213.0M |
| 008064206Jade Biosciences Inc | 6.7% | +0.0% | $101.2M |
| ELVNEnliven Therapeutics Inc | 6.2% | +0.0% | $94.2M |
| VRDNViridian Therapeutics Inc | 6.2% | +30.1% | $93.5M |
| ZBIOZenas Biopharma Inc | 4.0% | +0.0% | $59.9M |
| CBIOCrescent Biopharma Inc | 3.3% | +0.0% | $49.5M |
| APGEApogee Therapeutics Inc | 2.6% | +0.0% | $39.6M |
| FTHFaeth Therapeutics Inc | 1.2% | — | $18.1M |
| IKTInhibikase Therapeutics Inc | 1.2% | +0.0% | $17.5M |
What Fairmount Funds Management LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- FTH Faeth Therapeutics Inc1.2% of 13F
Added to
- VRDN Viridian Therapeutics Inc+30.1% shares
Reduced
No position shrank by more than 5%.
Sold out
- SYRE Spyre Therapeuticswas 14.6%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +218.5% /yr
- S&P 500 +20.1%
- 3 years
- +72.8% /yr
- S&P 500 +20.4%
- 5 years
- +51.8% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $1.5B | 12 |
| Q1 2026 | $1.4B | 12 |
| Q4 2025 | $1.3B | 13 |
| Q3 2025 | $1.1B | 17 |
| Q2 2025 | $771.9M | 17 |
| Q1 2025 | $644.6M | 15 |
| Q4 2024 | $1.0B | 17 |
| Q3 2024 | $1.2B | 15 |
| Q2 2024 | $885.1M | 13 |
| Q1 2024 | $917.4M | 15 |
| Q4 2023 | $946.5M | 16 |
| Q3 2023 | $831.2M | 20 |
Questions about Fairmount Funds Management LLC's portfolio
What stocks does Fairmount Funds Management LLC own?
Fairmount Funds Management LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 12 positions worth $1.5B. The largest are Oruka Therapeutics Inc (ORKA) at 23.3%, Dianthus Therapeutics Inc (DNTH) at 16.3%, Damora Therapeutics Inc (GLTO) at 15.0%, Cogent Biosciences Inc (COGT) at 14.1% and Jade Biosciences Inc at 6.7%.
What did Fairmount Funds Management LLC buy last quarter?
In Q2 2026, Fairmount Funds Management LLC added a new position in Faeth Therapeutics Inc (FTH) and Viridian Therapeutics Inc (VRDN) (+30.1% shares), compared with its Q1 2026 filing.
What did Fairmount Funds Management LLC sell last quarter?
In Q2 2026, Fairmount Funds Management LLC sold all of Spyre Therapeutics (SYRE), compared with its Q1 2026 filing.
How has Fairmount Funds Management LLC's portfolio performed?
A portfolio copying Fairmount Funds Management LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +72.8% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +218.5% against +20.1%. Over 5 years: +51.8% a year against +11.6%.
When is Fairmount Funds Management LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Fairmount Funds Management LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Fairmount Funds Management LLC manage?
Fairmount Funds Management LLC reported $5.8B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $1.5B.